CClinicalTrials.gg
WithdrawnNCT04647084Updated Aug 18, 2023

Pilot Trial: Comparing Buzzy to Intradermal Lidocaine for Peripheral IV Cannulation in Adults

A Phase 4 interventional study of Lidocaine 2% Injectable Solution and Buzzy in Pain, Acute and Patient Satisfaction, sponsored by Steward St. Elizabeth's Medical Center of Boston, Inc.. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Steward St. Elizabeth's Medical Center of Boston, Inc. · Phase 4, Interventional, and Prevention

Why this study was withdrawn
The investigators were unable to begin work on this study.
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

IV placement is necessary for surgical procedures. Unfortunately, some patients say that placing an IV is painful. The investigators are conducting this study to evaluate two techniques that could make the placement of the IV more comfortable.

Read the detailed description

Currently, some medical providers administer the IV without any pain-relieving techniques. Some medical providers inject a numbing medication underneath the skin prior to the IV placement. This requires an additional needle stick. Some medical providers place a device called Buzzy® on a patient's arm prior to the IV placement. The Buzzy® device is the combination of an ice pack and a vibrator in the shape of a bumble bee. Literature shows that the Buzzy® device makes IV placement more comfortable for children, but there is minimal data in regard to whether it is helpful for adult patients.

The investigators are conducting this study to compare the effectiveness of the Buzzy® device with that of the injection of numbing medication underneath the skin for IV placement in adults. This device has been FDA approved for use.

02

Conditions studied

  • Pain, Acute
  • Patient Satisfaction

Browse trials for

03

In context

Acute Pain

876 studies on the registry are indexed under Acute Pain; 154 are open to participants now.

Browse Acute Pain studies →

Lead sponsor

Steward St. Elizabeth's Medical Center of Boston, Inc. is the lead sponsor of 23 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Adults ages 18 to 99
  2. Non-pregnant women and men
  3. Adults that are able to consent
  4. Patients requiring intravenous catheter insertion for their operation/procedure

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Intradermal Lidocaine 2%

    Drug: Lidocaine 2% Injectable Solution

  • Experimental
    Buzzy

    Device: Buzzy

Interventions

  • DrugLidocaine 2% Injectable Solution

    An elastic band will be placed around the subject's arm, and the elastic band will be removed once the IV is inserted. After the elastic band is placed on the subject's arm, the arm will be cleaned, and then a small skin wheel will be created with the lidocaine that will be injected very close to where the IV will be placed. The IV will be placed within about a minute from the time when the lidocaine was injected.

  • DeviceBuzzy

    The Buzzy vibrating ice pack will be placed on the subject's arm with an elastic band around it, and it will remain there as the arm is cleaned and prepped and the IV inserted. The Buzzy device will be removed once the IV is inserted.

06

What researchers measure

Primary outcomes

  1. Pain with IV Cannulation based on the Visual Analog Scale

    How much pain do adult patients experience with peripheral IV cannulation when Buzzy® device is used versus when intradermal lidocaine 2% is used? The Visual Analog Scale is used for linear measurement of pain, where the minimum number is 0 (no pain) and the maximum number is 10 (unimaginable pain).

    Time frame: 5-20 minutes

Secondary outcomes

  1. Satisfaction with IV cannulation based on the Numerical Rating Scale

    How much satisfaction do adult patients experience with peripheral IV cannulation when Buzzy® device is used versus when intradermal lidocaine 2% is used? The Numerical Rating Scale is used for linear measurement of satisfaction, where the minimum number is 1 (very dissatisfied) and the maximum number is 5 (very satisfied).

    Time frame: 5-20 minutes

  2. Number of IV cannulation attempts

    How does first attempt during peripheral intravenous cannulation in adult patients compare when Buzzy® device is used versus when intradermal lidocaine 2% is used?

    Time frame: 5-20 minutes

  3. Pain related to IV size based on the Visual Analog Scale

    Does size of the peripheral intravenous catheter affect the pain that adult patients experience with peripheral IV cannulation? The Visual Analog Scale is used for linear measurement of pain, where the minimum number is 0 (no pain) and the maximum number is 10 (unimaginable pain).

    Time frame: 5-20 minutes

  4. Pain related to IV location based on the Visual Analog Scale

    Does location of the peripheral intravenous catheter placement affect the pain that adult patients experience with peripheral IV cannulation? The Visual Analog Scale is used for linear measurement of pain, where the minimum number is 0 (no pain) and the maximum number is 10 (unimaginable pain).

    Time frame: 5-20 minutes

07

Study locations

1 site
  • St. Elizabeth's Medical Center
    Brighton, Massachusetts 02135, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 25, 2020
  • Informed consent form · Sep 11, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04647084
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Responsible party
Sponsor
First posted
Nov 30, 2020
Start date
Oct 15, 2022 (estimated)
Primary completion
Oct 15, 2024 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Aug 18, 2023

Study contacts

Michael Schoor, MD
principal investigator · physician

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion